Does serum neural autoantibody positivity alone indicate autoimmune neurologic disease?

Neural autoantibody testing is most informative when interpreted as part of a syndrome-based, compartment-aware evaluation—not as a standalone serum diagnosis.

Clinical and diagnostic evidence

• A compatible subacute neurologic phenotype is the primary anchor for autoimmune neurologic disease. For possible autoimmune encephalitis, phenotype-first criteria require a fitting presentation, at least one corroborating clinical/paraclinical feature, and reasonable exclusion of alternatives; antibody findings refine rather than replace this assessment.
• Serum positivity can support disease when antigen specificity, assay quality, titer, and phenotype align. In contrast, in a retrospective broad-panel testing cohort, 61.8% of positive results were adjudicated false positive; 95.2% of false-positive results were serum-only. This illustrates the limited diagnostic value of isolated serum reactivity in low-pretest-probability settings.
• CSF inflammation or disease-concordant CSF antibodies adds important support. Paired serum–CSF testing is particularly useful because sensitivity differs by antibody: CSF is especially informative for NMDAR antibodies, whereas serum may be more sensitive for LGI1 or CASPR2. Lack of supportive CSF findings therefore reduces support but does not universally exclude disease.

Mechanistic interpretation

• Direct antibody pathogenicity requires access to the relevant neural compartment. CNS access may occur through blood–brain barrier disruption or intrathecal B-cell/plasma-cell antibody production.
• Once present, surface-antigen antibodies can act directly: anti-NMDAR IgG can cross-link and internalize receptors, while LGI1 antibodies can disrupt LGI1–ADAM22/ADAM23 signaling. Peripheral antibodies may reach relatively accessible roots, ganglia, or terminals; antiganglioside antibodies can cause complement-mediated injury in models.
• By contrast, antibodies to intracellular antigens such as Hu or Yo are generally biomarkers of a paraneoplastic, cytotoxic-T-cell–associated immune response, rather than established direct mediators of neuronal injury.

Bottom line

• Serum neural autoantibody positivity alone—especially without a compatible neurologic syndrome or corroborating CSF evidence—may not indicate autoimmune neurologic disease. Target access is essential for direct antibody effects, but specificity, titer, persistence, and effector function also determine clinical relevance.